Susan G Dorsey, Ian R Kleckner, Debra Barton, Karen Mustian, Ann O'Mara, Diane St Germain, Guido Cavaletti, Suzanne C Danhauer, Dawn Hershman, Andrea G Hohmann, Ahmet Hoke, Judith O Hopkins, Katherine P Kelly, Charles L Loprinzi, Howard L McLeod, Supriya Mohile, Judith Paice, Julia H Rowland, Daniela Salvemini, Rosalind A Segal, Ellen Lavoie Smith, Worta McCaskill Stevens, Michelle C Janelsins
Although recent scientific advances have improved our understanding of basic biological mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN), few interventions are available to prevent or treat CIPN. While some biological targets from preclinical studies show promise in non-human animal models, few targets have been translated to successful clinical trials. To address this problem, the National Cancer Institute's (NCI's) Symptom Management and Health-Related Quality of Life Steering Committee convened a meeting of experts in the CIPN and oncology symptom management fields to participate in a Clinical Trials Planning Meeting (CTPM)...
January 31, 2019: Journal of the National Cancer Institute